The US Food and Drug Administration (FDA) has warned the public against the use of Innova Medical Group’s SARS-CoV-2 Antigen Rapid Qualitative Test for diagnostic purposes.
The agency did not authorise, clear or approve the test for commercial supply or use in the country.
In its warning, the regulator highlighted concerns that the test’s performance had not been adequately evaluated, which could be a health risk.
